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Convalescent plasma has been used worldwide to treat patients hospitalized with
coronavirus disease 2019 (COVID-19) and prevent disease progression. Despite global
usage, uncertainty remains regarding plasma efficacy, as randomized controlled trials
(RCTs) have provided divergent evidence regarding the survival benefit of convalescent
plasma. Here, we argue that during a global health emergency, the mosaic of evidence
originating from multiple levels of the epistemic hierarchy should inform contemporary
policy and healthcare decisions. Indeed, worldwide matched-control studies have
generally found convalescent plasma to improve COVID-19 patient survival, and
RCTs have demonstrated a survival benefit when transfused early in the disease
course but limited or no benefit later in the disease course when patients required
greater supportive therapies. RCTs have also revealed that convalescent plasma
transfusion contributes to improved symptomatology and viral clearance. To further
investigate the effect of convalescent plasma on patient mortality, we performed a
meta-analytical approach to pool daily survival data from all controlled studies that
reported Kaplan–Meier survival plots. Qualitative inspection of all available Kaplan–Meier
survival data and an aggregate Kaplan–Meier survival plot revealed a directionally
consistent pattern among studies arising from multiple levels of the epistemic hierarchy,
whereby convalescent plasma transfusion was generally associated with greater patient
survival. Given that convalescent plasma has a similar safety profile as standard plasma,
convalescent plasma should be implemented within weeks of the onset of future
infectious disease outbreaks.
Keywords: convalescent plasma therapy, COVID-19, SARS-CoV-2, passive antibody transfer, Kaplan–Meier
analysis
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INTRODUCTION
In response to the coronavirus disease 2019 (COVID-19)
pandemic caused by the novel human severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), convalescent plasma
has been used worldwide to treat hospitalized patients and
prevent progression of disease in non-hospitalized patients (1–
4). Due to the limited number of therapeutic alternatives for
COVID-19, widespread optimism for antibody therapy has also
led to the commercial production of other immunoglobulin
therapies, including monoclonal antibodies and hyperimmune
products (5, 6). However, despite global usage, clinicians and
researchers have struggled to reach consensus regarding the
clinical utility of convalescent plasma. Although signatures of
efficacy have emerged consistently from worldwide matched-
control studies (7), there remains a paucity of data from large
randomized clinical trials (RCTs) demonstrating efficacy. Recent
reviews and meta-analyses have also generated disharmonious
conclusions regarding the effect of convalescent plasma on
COVID-19 patient outcomes, such as mortality and clinical
improvement. A pragmatic meta-analysis by our group that
included data from both RCTs and matched-control studies
demonstrated a mortality reduction attributed to convalescent
plasma in COVID-19 patients (8). Conversely, recent reviews
that adhered to stricter study inclusion rules and aggregated
only RCT data concluded that either convalescent plasma had
no effect on mortality or that insufficient evidence exists to
determine efficacy (9, 10). In addition, data emerging from the
RECOVERY Trial in the United Kingdom showed no survival
benefit of convalescent plasma in its overall cohort that was
severely ill but demonstrated trends toward efficacy when plasma
was transfused to patients who were earlier in the disease course
and did not require supplemental oxygen or corticosteroids (11).
These contradictory findings present a challenge for physicians in
deciding the therapeutic strategy for COVID-19 patients.
We argue that during a global health emergency like
a pandemic, evidence originating from multiple levels of
the epistemic evidence hierarchy should be used to inform
contemporary policy and healthcare decisions. Such an approach
is needed for a complex therapy like convalescent plasma where
efficacy depends on the quality of the plasma, the timing of
administration, and the immunological status of the patient
(12). Thus, this graphical review aims to showcase the mosaic




Briefly, convalescent plasma represents a form of passive
antibody therapy that relies on the transfer of pathogen-
specific antibodies from a recovered patient for the purpose
of preventing or treating disease (13). Unlike vaccines and
monoclonal antibodies, convalescent plasma therapy requires
limited development or infrastructure, requiring no more than
the availability of disease survivors willing to donate plasma
and standard blood collection infrastructure to collect and
distribute convalescent plasma (14). With no vaccines or
monoclonal antibodies available at the onset of the COVID-19
pandemic, convalescent plasma was an immediately deployable
option (14, 15). In addition, for this reason, convalescent
plasma can be readily used in low resource settings across
the globe.
Convalescent plasma is also adaptable to changing conditions.
As variant SARS-CoV-2 strains continue to emerge, convalescent
plasma donated by survivors of infections with variant strains
represents an immediately deployable therapeutic for patients
identified with a variant infection, whereas other immune
therapies may require (re)development tomore specifically target
new viral strains (16–19).
To effectively neutralize SARS-CoV-2 and confer clinical
benefit, convalescent plasma must adhere to the three
fundamental principles of passive antibody therapy (12).
Convalescent plasmamust (20–22):
i) Contain specific antibodies against the pathogen, the
SARS-CoV-2 virus
ii) Contain a sufficient level of anti-SARS-CoV-2 antibody, and
iii) Be transfused prophylactically or early in the disease course.
CONVALESCENT PLASMA FOR PREVIOUS
RESPIRATORY VIRAL OUTBREAKS
The widespread use of convalescent plasma in the COVID-19
pandemic was founded on its rich history of efficacy against
human respiratory viral infections. Indeed, the first Nobel Prize
in Physiology or Medicine was awarded for the discovery
of convalescent plasma (serum) therapy for diphtheria (15).
Since the late nineteenth century, convalescent plasma has
been used to mitigate several outbreaks caused by human
respiratory viruses. A meta-analysis of eight studies (n =
1,703 patients) found that convalescent plasma reduced the
absolute risk of death by 21% in patients with H1N1 viral
infections during the 1918 influenza pandemic (23). Subgroup
analysis of patients transfused with convalescent plasma within
3 days of illness onset demonstrated a 41% lower risk of
death compared to patients transfused four or more days
after illness onset, highlighting an important role for timely
convalescent plasma transfusion (23). Convalescent plasma has
also been associated with positive clinical outcomes in recent
outbreaks caused by other coronaviruses, including the 2001
SARS1 epidemic and the 2012Middle East Respiratory Syndrome
(MERS) (24–26). For instance, in 80 patients diagnosed with
SARS1, patients transfused with convalescent plasma within
2 weeks of illness onset were more likely to be discharged
by day 22 of hospitalization than patients treated later in the
disease course (24). Although most of the historical evidence
for convalescent plasma emerged from retrospective matched-
control designs and single-arm studies, the favorable efficacy
data and positive safety signals provided strong precedent for
rapid implementation at the onset of the COVID-19 pandemic
(14, 20).
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CONVALESCENT PLASMA THERAPY FOR
COVID-19: EXPERIMENTAL EVIDENCE
In the context of the COVID-19 pandemic, the anticipated
primary mechanism for the clinical benefit of convalescent
plasma immunotherapy is SARS-CoV-2 viral neutralization
(27, 28). Virus neutralization occurs when antibodies bind to
the spike protein and prevent binding to the host cellular
receptors. In addition to viral neutralization, convalescent plasma
includes antibodies that mediate three other antiviral functions
against SARS-CoV-2: (i) complement activation, (ii) antibody-
dependent cellular cytotoxicity, and (iii) phagocytosis (29). The
antiviral effect of convalescent plasma is supported by RCTs and
observational studies, which have consistently shown a reduction
in viral load following transfusion (3, 27, 30).
COVID-19 pathogenesis begins with an early viral phase that
can progress to a life-threatening inflammatory phase (31). The
viral phase is characterized by SARS-CoV-2 virus replication
that is accompanied by variable symptoms and triggers an
endogenous antibody response around days 10–12 of infection
(32). Some individuals may progress to an inflammatory phase
that may clear the virus but impairs pulmonary gas exchange and
in some cases causes respiratory failure and death (31, 33, 34).
Thus, early convalescent plasma transfusion during the viral
phase is effective because viral neutralization prevents disease
progression to the severe inflammatory phase. Consistent with
this view, convalescent plasma administration in COVID-19 is
followed by reduction in markers of inflammation (35, 36). A
synthesis of these observations suggests that early administration
of convalescent plasma reduces viral burden through antibody-
mediated antiviral effects, which in turn prevents inflammation
promoting a survival benefit by improving oxygen exchange in
the lung.
Animal Studies
During the COVID-19 pandemic, several animal studies
performed in parallel with human clinical investigations have
demonstrated convalescent plasma efficacy in experimental
SARS-CoV-2 infection. For example, convalescent serum from
Syrian hamsters elicited an antiviral effect when administered
to infected animals (37). Similarly, among SARS-CoV-2-infected
green monkeys, transfusion of convalescent plasma from the
same species reduced lung pathology, viral shedding, and
inflammation (38). In addition, administration of human
convalescent plasma protected mice expressing the human
ACE2 receptor from SARS-CoV-2 infection (39). These studies
illustrate that animal and human convalescent plasma contains
virus-neutralizing antibodies that mediate protective effects in
animal models of SARS-CoV-2 infection.
CONVALESCENT PLASMA THERAPY FOR
COVID-19: MOSAIC OF CLINICAL
EVIDENCE
To date, 11 RCTs (11, 27, 30, 40–47) and 24 matched-control
studies (3, 4, 48–69) have investigated convalescent plasma
therapy for COVID-19. Of these studies, 16 presented survival
data using a Kaplan–Meier diagram (11, 27, 41, 43, 46, 47, 50,
52, 59–62, 64, 69–71). To investigate the impact of convalescent
plasma on COVID-19 patient survival over time, we extracted
daily survival data from all available Kaplan–Meier diagrams
using an online data extraction tool (WebPlotDigitizer v4.4,
Pacifica, CA, USA). Kaplan–Meier survival plots were replotted
for each study. Aggregate Kaplan–Meier survival plots were
computed by pooling the derived number of deaths per day
from the daily survival rate and reported number of patients at
risk. For aggregate survival plots, 95% confidence intervals were
calculated by Greenwood’s formula (72). This meta-analytical
approach provides greater temporal resolution of survival data
compared to conventional meta-analyses that rely on the overall
survival rate at the end of the study period (73). Figures were
generated with R software (R Core Team, Vienna, Austria) and
GraphPad Prism (GraphPad Software, San Diego, CA, USA).
Qualitative inspection of the available Kaplan–Meier survival
data from 16 controlled studies revealed a directionally consistent
pattern whereby convalescent plasma transfusion was associated
with greater patient survival compared to non-transfused
patients (Figure 1) (11, 27, 41, 43, 46, 47, 50, 52, 59–62,
64, 69–71). Pooling all available Kaplan–Meier survival data
showed a 14% relative improvement in COVID-19 patient
28-day survival associated with convalescent plasma (84 vs.
74%) (Figure 2A). We offer the caveat that due to the
large sample size of the RECOVERY Trial (11), these data
were not included in this aggregation but reported separately
(Figure 2D). The RECOVERY Trial found no difference in
28-day mortality between COVID-19 patients treated with
convalescent plasma and non-transfused patients (24 vs. 24%)
(11). The general survival benefit associated with convalescent
plasma has been observed worldwide including studies that were
heterogenous for health system type and infectious disease or
critical care infrastructure, timing relative to pandemic onset,
convalescent plasma antibody titer and volume, and patient
disease severity (Supplementary Figure 1). This consistency
of evidence across nations with different health systems
supports the notion that convalescent plasma therapy is
effective against COVID-19.
Randomized Clinical Trials
Signatures of convalescent plasma efficacy have emerged from
some but not all RCTs. Inspection of available Kaplan–Meier
survival data from seven published RCTs revealed a directionally
consistent pattern whereby convalescent plasma appeared to
improve COVID-19 patient survival compared to patients that
received standard of care (Figure 1) (11, 27, 41, 43, 46, 47, 71).
Pooling these available survival data demonstrated a 11% relative
improvement in 28-day survival associated with convalescent
plasma compared to control (88 vs. 79%) (Figure 2B). While
the effect of convalescent plasma on mortality was found to be
statistically significant in only two RCTs (42, 71), it is important
to highlight that signals of efficacy have emerged despite several
limitations, including trials that (i) were underpowered due to
declining local infection rates and early termination (27, 43),
(ii) transfused convalescent plasma units with unknown or low
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FIGURE 1 | Kaplan–Meier survival plots from worldwide controlled studies investigating convalescent plasma therapy for coronavirus disease 2019 (COVID-19).
Available Kaplan–Meier survival data from worldwide controlled studies [n = 7 randomized clinical trials (11, 27, 41, 43, 46, 47, 71) and n = 9 matched-control studies
(50, 52, 59–62, 64, 69, 70)] was extracted and replotted. Each panel represents data from one study, where the orange line represents the survival of the cohort
transfused with convalescent plasma, and the blue line represents the survival of the cohort that received standard of care or placebo transfusion. The label for each
study provides the first author name, location, and study type, where matched-control studies are denoted by (M) and randomized clinical trials are denoted by (R).
For each study, sample sizes from the number at risk at study onset are presented for the treatment and control cohorts. No statistical analyses were performed.
Interpretation: Qualitative inspection of the Kaplan–Meier survival data from 16 controlled studies revealed a directionally consistent pattern whereby convalescent
plasma transfusion was associated with greater patient survival compared to non-transfused patients.
anti-SARS-CoV-2 antibody levels (30), (iii) transfused severely
ill patients that had progressed to severe COVID-19 (11, 27),
and (iv) used prepositioned plasma units, which may not have
accounted for SARS-CoV-2 variants (18, 19). Transfusion of
low antibody titer plasma to patients with severe COVID-19
reduces the opportunity to achieve the survival benefit associated
with convalescent plasma. Due to the large sample size of
the RECOVERY Trial [n = 11,558; (11)], these data were not
included in the aggregate RCT Kaplan–Meier plot (Figure 2B)
but reported separately (Figure 2D). The RECOVERYTrial likely
did not find an effect of convalescent plasma in their overall
cohort due to the large proportion of severely ill patients (24%
overall mortality) who were treated late in the disease course
(median time to transfusion, 9 days). Corticosteroids, which
interfere with antibody function, were used in more than 90% of
study patients in both arms (11).
Nonetheless, some signals of efficacy emerged from subgroup
analyses of the RECOVERY Trial data (11). First, in four likely
overlapping groups of patients characterized as representing
earlier disease, significant or near-significant lowering of
mortality was seen with convalescent plasma: among patients
transfused within 7 days of symptom onset [odds ratio, 0.92
(95% confidence interval, 0.83–1.03)], patients not receiving
corticosteroids [odds ratio, 0.78 (95% confidence interval, 0.58–
1.05)], patients not on supplemental oxygen [odds ratio, 0.83
(95% confidence interval, 0.58–1.18)], and patients without an
endogenous anti-SARS-CoV-2 antibody response at time of
transfusion [see Figure 2E—odds ratio, 0.94 (95% confidence
interval: 0.84–1.06)] (11). These trends toward a survival
benefit with early plasma transfusion are consistent with the
RCT by Libster et al., which observed a ∼50% reduction in
progression to severe COVID-19 respiratory disease whenmildly
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FIGURE 2 | Aggregate Kaplan–Meier survival plots from all available controlled studies investigating convalescent plasma therapy for COVID-19. (A) Pools all
controlled studies [n = 6 randomized clinical trials (11, 27, 41, 43, 47, 71, 74) and n = 9 matched-control studies (50, 52, 59–62, 64, 69, 70)] with available
Kaplan–Meier survival data except for the large randomized clinical trial, the RECOVERY Trial. (B) Pools randomized clinical trials (n = 6) with available data except for
the RECOVERY Trial. (C) Pools matched-control studies (n = 9) with available data. (D) Shows the RECOVERY Trial data from the overall cohort, and (E) shows the
RECOVERY Trial data from the subgroup of patients that were seronegative at the time of plasma transfusion. Available 28-day Kaplan–Meier survival data from
worldwide controlled studies was extracted, pooled, and replotted. For each panel, the orange line represents the survival of the cohort transfused with convalescent
plasma, and the blue line represents the survival of the cohort that received standard of care or placebo transfusion. Error bands represent 95% confidence intervals.
The 28-day survival (%) for the aggregate convalescent plasma cohort and the aggregate control cohort is presented. The table at the bottom of each panel presents
the number at risk on the day of enrollment or randomization, day 10, day 20, and day 28 for the aggregate convalescent plasma cohort and the aggregate control
cohort. Interpretation: The aggregate survival data from (A) all controlled studies except for the RECOVERY Trial, (B) all randomized clinical trials except for the
RECOVERY Trial, and (C) all matched-control studies revealed a consistent pattern whereby convalescent plasma transfusion was associated with greater patient
survival compared to non-transfused patients. (D) The overall RECOVERY Trial cohort demonstrated no survival benefit of convalescent plasma. (E) The modest
efficacy signal from the RECOVERY Trial subgroup of seronegative patients supports the concept that early plasma transfusion reduces patient mortality.
ill patients were transfused with convalescent plasma screened for
appropriate level of antibody and a 73% reduction when plasma
with antibody above the median was used (45).
Not all meta-analytical approaches support the impact of
convalescent plasma on patient survival. A recent Cochrane
review and meta-analysis that was restricted to only a few
RCTs found insufficient evidence to draw conclusions regarding
plasma efficacy (10). In addition, a meta-analysis of 10 RCTs by
Janiaud et al. found that convalescent plasma was not associated
with improved survival among COVID-19 patients (9). This
latter meta-analysis was strongly affected by RECOVERY Trial
data, which had a statistical weight of 90%. By contrast, our
pragmatic meta-analysis of RCT data showed that overall in all
studies, patients transfused with convalescent plasma exhibited
reduced mortality rates compared to non-transfused COVID-
19 patients (11 vs. 16% mortality; OR, 0.65; 95% CI, 0.43, 0.98,
P = 0.04) (8). For the interpretation of these results, we offer the
caveat that our prior analyses excluded the trial by Agarwal et al.
(30) due to the low plasma quality and was published before the
release of the RECOVERY Trial data (11). Completion of several
ongoing RCTs designed in accordance with the key principles
of passive antibody therapy will provide more comprehensive
data regarding the effect of convalescent plasma on COVID-19
patient survival.
Even among trials that did not find a survival benefit, RCTs
identified positive effects of convalescent plasma on other clinical
outcomes including symptomatology, oxygen requirements, and
viral clearance. For example, Agarwal et al. found that a
significantly greater proportion of transfused patients exhibited
improved viral clearance and resolution of shortness of breath
and fatigue within 1 week of randomization (30). Similarly,
among patients with severe disease, Li et al. observed that
transfused patients exhibited greater viral clearance and shorter
times to reductions in supplemental oxygen and hospital
discharge (27). Other RCTs have made similar observations
(40–43, 45, 46). These additional clinical outcomes compliment
positive safety data to support convalescent plasma therapy for
patients hospitalized with COVID-19 (75, 76).
Matched-Control Studies
In contrast to RCTs, matched-control studies have generally
observed a survival benefit associated with convalescent plasma
therapy. Inspection of available Kaplan–Meier survival data from
nine published matched-control studies showed a consistent
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pattern whereby convalescent plasma appeared to improve
COVID-19 patient survival compared to non-transfused patients
(Figure 1) (50, 52, 59–62, 64, 69, 70). Combining these available
survival data demonstrated an 11% relative improvement in 28-
day survival associated with convalescent plasma compared to
control patients (82 vs. 74%) (Figure 2C). Our recent meta-
analysis that aggregated data from 20 matched-control studies
supports these findings (8). These analyses indicated that patients
transfused with convalescent plasma exhibited a 43% relative
reduction in mortality compared to patients receiving standard
treatments (21 vs. 29% mortality; OR, 0.57; 95% CI, 0.45,
0.72; P < 0.001) (8). The contrasting mortality benefit between
matched-control studies and larger multicenter RCTs raises
the possibility that locally sourced plasma administered shortly
after donation may increase convalescent plasma efficacy against
local variants in real time as they emerge (17). Compared
to RCTs, matched-control studies are inherently predisposed
to greater bias risk (77). However, several studies observed
convalescent plasma efficacy using rigorous propensity matching
for key variables such as age, sex, disease severity and oxygen
requirements, and comorbidities (52, 64, 69, 70). For example, a
large propensity-matched study by Salazar and colleagues found
that transfusion of high-titer convalescent plasma within 44 h
of hospitalization reduced mortality among patients hospitalized
with COVID-19 (64).
Other Clinical Evidence
The evidence mosaic for convalescent plasma efficacy also
includes data from dose–response studies and case series of
vulnerable immunocompromised patient populations. On the
basis that anti-SARS-CoV-2 neutralizing antibodies represent
the primary mechanism for plasma efficacy, we previously
examined the dose–response relationship between antibody
titer level and 30-day mortality among 3,082 transfused
patients via the United States Expanded Access Program for
convalescent plasma (78). Transfusion of higher titer plasma
was associated with lower 30-day mortality than transfusion
of plasma with lower antibody titers (22 vs. 30%) (78).
Convalescent plasma conferred a survival benefit only in
patients that were transfused earlier in the disease course,
as this association was not observed in patients that were
mechanically ventilated at the time of transfusion (78). Similarly,
in the Argentine Expanded Access Program experience (n =
4,719), patients transfused with convalescent plasma within
3 days of hospitalization demonstrated a 65% reduction in
mortality compared to patients transfused after 7 days of
hospitalization (2).
Evidence of efficacy has also emerged from studies of
convalescent plasma therapy in immunocompromised
patients who cannot generate an innate immune response
(79). In a case series of three COVID-19 patients with
X-linked agammaglobulinemia (XLA) who required
supplemental oxygen, convalescent plasma transfusion
was associated with rapid improvements in oxygen
requirements and symptomatology in all patients (80). These
data align with observations from the RECOVERY Trial
subgroup analysis, which demonstrated a trend toward
a reduction in mortality associated with convalescent
plasma transfusion among patients that did not generate
a SARS-CoV-2 antibody response (11). These observations
also provide a unique “experiment of nature” for
convalescent plasma, as the rapid recovery of these





Challenges associated with convalescent plasma therapy likely
limit clinical evidence and interpretation of the mosaic of
evidence. First, the therapeutic dose per se of convalescent
plasma that imposes viral neutralization and improves the
recipient’s clinical condition is unknown and represents a
highly complicated concept. In addition, a “gold standard”
serological assay to detect antibodies to SARS-CoV-2 has
not been identified, and the assays in use are investigational
(81). Thus, some studies likely failed to identify a clinical
benefit of convalescent plasma due to low antibody levels,
and between-trial differences in both antibody levels and
assays may contribute to variability in outcomes between
trials. Given the limitations of low antibody levels, the
US Food and Drug Administration (FDA) now requires
use of convalescent plasma with higher antibody levels,
thereby eliminating the use of low antibody convalescent
plasma (1).
Second, the precise therapeutic window of convalescent
plasma that corresponds to antiviral effects is unknown
but convalescent plasma likely has limited effects late
in the COVID-19 disease course, for example, among
patients that require mechanical ventilation. Some studies
that reported no effect of convalescent plasma transfused
patients that were in advanced stages of COVID-19 respiratory
failure attributed to an excessive inflammatory response
(11, 27, 30). These results should not be surprising and may
be interpreted as confirming the limitations of the therapeutic
window of convalescent plasma rather than interpreted
as “null findings” with respect to therapeutic effectiveness
of plasma.
Evidence emerging from RCTs suggests that the therapeutic
window of convalescent plasma coincides with that of the
antiviral remdesivir, which was associated with greater patient
recovery when administered prior to transition to high-flow
oxygen and mechanical ventilation (82). Two other experimental
COVID-19 therapies may be used to treat patients outside
the therapeutic window of convalescent plasma. Prior to
hospitalization, COVID-19 patients may receive monoclonal
antibodies, which reduce both viral load and the time to symptom
resolution in non-hospitalized individuals with COVID-19 (83,
84). Upon progression to severe COVID-19 requiringmechanical
ventilation, dexamethasone represents a promising experimental
therapy for stemming the inflammatory phase of COVID-19 and
improving patient survival (85).
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CONCLUSIONS AND FUTURE
DIRECTIONS
Currently, a mosaic of evidence from varying epistemic levels
exists for convalescent plasma therapy.While most RCTs indicate
that convalescent plasma confers no survival benefit when used
in severely ill hospitalized COVID-19 patients, these same trials
have identified clinical improvements, such as viral clearance
and reduced supplemental oxygen, following plasma transfusion.
In addition, although two of the largest RCTs found no effect
of convalescent plasma, these trials were limited by low plasma
quality (30) or a high proportion of severely ill patients
concomitantly treated with corticosteroids [RECOVERY Trial
(11)], which can interfere with antibody function. In contrast,
worldwide matched-control studies have consistently found
that convalescent plasma improves COVID-19 patient survival.
Qualitative inspection of individual and aggregate Kaplan–Meier
survival curves from RCTs and matched-control studies reveals a
directionally consistent pattern, suggesting convalescent plasma
efficacy in COVID-19 patients. Importantly, worldwide studies
have consistently found that convalescent plasma therapy is as
safe as standard plasma. Thus, while individual lines of evidence
forming the mosaic each have foibles, such as potential bias in the
observational studies and late usage of low titer plasma in some
RCTs, the composite mosaic encourages the use and continued
study of convalescent plasma. In this regard, there have been five
major infectious disease outbreaks in 21 years, namely, SARS,
MERS, Zika virus, Ebola, and COVID-19, and convalescent
plasma therapy was used for all but Zika virus. Convalescent
plasma epitomizes a “common sense” therapeutic, which, if
implemented rapidly in future infectious disease outbreaks and
in a manner that abides by the core principles of passive antibody
therapy, can continue to serve as a stopgap therapy until more
effective strategies are identified.
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